Testing a new heart device that closes a small hole in people with stroke

Trial details

Who runs it

Recross Cardio, Inc.

Trial code

NCT07698951

Record updated

13 July 2026

Original description

The goal of this clinical trial is to test a new heart device called P3 Occluder System in patients who have a small opening between the upper chambers of the heart (called a Patent Foramen Ovale or PFO) and have experienced a stroke that may be related to this heart opening. The main question it aims to answer is:Read full original descriptionShow less

Evaluating Percutaneous Repair Of The Atrial Septum With A Novel PFO Occluder: The PROTEA-PFO OUS Study

The goal of this clinical trial is to test a new heart device called P3 Occluder System in patients who have a small opening between the upper chambers of the heart (called a Patent Foramen Ovale or PFO) and have experienced a stroke that may be related to this heart opening. The main question it aims to answer is:

• Is the P3 Occluder System safe and effective for closing a PFO in patients who have had a stroke that could be related to a PFO.

Participants will:

* Undergo the procedure to implant the P3 Occluder System, if deemed appropriate. * Visit their doctor at 1 month, 3 months, 6 months, and 1 year after the procedure for follow up exams. * Answer a phone call from study staff at 2 years and 3 years after the procedure to answer a survey.

Inclusion: Patient must be ≥ 18 and ≤ 65 years of age; Diagnosis of PFO, defined as visualization of microbubbles per TEE in the left atrium within three cardiac cycles from the right atrial opacification demonstrating right-to-left shunting at rest and/or during Valsalva release; Ischemic stroke, defined as acute focal neurological deficit, presumed to be due to focal ischemia and confirmed by MRI or CT to have a neuroanatomically relevant cerebral infarct; Modified Rankin score (mRS) ≤ 3; Appropriate PFO anatomy for implantation of the investigational device as evaluated and determined by independent committee; Patient is willing and capable of providing informed consent; Prior to index procedure (7-day window), persons of childbearing potential must have a negative pregnancy test.

Exclusion: Myocardial Infarction (MI) or unstable angina within the previous 180 days; Active endocarditis or other infection that may preclude implantation of the investigational device; Known hypercoagulable state that would require full anticoagulation. Minimum testing to include lupus anticoagulant, anticardiolipin antibodies, beta-2-glycoprotein, homocysteine; Any disorder in the investigator's opinion that could interfere with compliance of safety evaluation or require premature discontinuation of antiplatelet regime post-implantation, as well as any severe concurrent illness that would limit life expectancy (e.g., malignancies); Currently an active subject in an investigational drug or device study that could confound the results of this study; Any prior percutaneous cardiovascular intervention for AF ablation; Other identifiable causes of stroke, including but not limited to aortic arch plaques (protruding >4 mm into the lumen), large artery atherosclerotic disease proximal to the territory of the index stroke, an established cardioembolic source, small-vessel occlusive disease, or arterial dissection, presence of left atrial appendage thrombus; Other arteriopathy of the intracranial or extracranial vessels with >50% stenosis proximal to the territory of the index stroke; History of atrial tachycardia, atrial fibrillation or flutter, AV block, or ventricular arrhythmia requiring antiarrhythmic medication, pacemaker, or AICD; Severe liver disease (e.g., documented cirrhosis or active hepatitis); Severe lung insufficiency (e.g., need for supplemental oxygen or chronic steroid medications); Uncontrolled hypertension, defined as sustained elevated blood pressure >140/90 mm Hg; Severe pulmonary artery hypertension, defined as pulmonary systolic pressure of >50mmHg; Increased bleeding risk such as severe liver failure, active peptic ulcer, proliferative diabetic retinopathy, history of severe bleeding (e.g.: gastrointestinal bleeding, macroscopic hematuria, intraocular bleeding, intracranial or cerebral hemorrhage), or other history of bleeding or coagulopathy; Subjects not able to discontinue anticoagulation for indications other than then index stroke; Any significant valve dysfunction that contraindicates PFO closure or increased pulmonary vascular resistance/severe pulmonary hypertension; Known nickel allergy that, in the opinion of the investigator, poses a safety risk with regards to participation in the trial; Left ventricular dilated cardiomyopathy with LVEF <35%; Severe renal failure ( Stage 4 CKD, eGFR <30) or patient requiring dialysis; Uncontrolled hyperglycemia, defined as HbA1c value >8% (IFCC: >64 mmol/mol); Life expectancy < 2 years; Intracardiac thrombus or tumor; Left ventricular aneurysm or akinesis; Moderate to severe mitral valve stenosis or severe mitral regurgitation; Aortic valve stenosis (mean gradient >20 mmHg) or severe regurgitation; Any valve vegetation or Lambl's excrescence of any left-sided valve; Another source of right-to-left shunts identified at baseline, including an atrial septal defect and/or fenestrated septum and pulmonary arteriovenous malformation; Subjects contraindicated for aspirin or clopidogrel; Contraindication for transesophageal echocardiography (TEE) or intracardiac echocardiography (ICE).

ClinicalTrials.gov NCT07698951